Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo
K D Bardhan
a Rotherham General Hospitals NHS
Trust, Rotherham, b Astra Clinical Research
Unit, Edinburgh, c Royal Postgraduate Medical School, Hammersmith
Hospital, London, UK
Correspondence to: Dr K D Bardhan, Rotherham General
Hospitals NHS Trust, Moorgate Road, Rotherham S60 2UD, UK. Accepted for publication 16 April 1998 Aims Keywords:
erosive oesophagitis;
long term maintenance
treatment;
omeprazole
To investigate the efficacy of daily
maintenance treatment with omeprazole 10 mg in reducing the relapse
rate of healed erosive oesophagitis.
Methods
Three hundred patients with erosive
oesophagitis (grade 2 or greater) received omeprazole 20 mg daily for
12 weeks, followed by 40 mg daily for a further 12 weeks if required.
After healing, patients were randomised to double blind treatment with omeprazole 10 mg daily or placebo for up to 18 months. On relapse the
treatment cycle was repeated.
Results
The cumulative healing rate at 12 weeks
in the initial healing period was 95%, and 96% and 98% on rehealing
courses after relapse in the first and second maintenance periods
respectively. After 12 weeks of treatment, 98% of patients were free
from heartburn and 97% were free of all reflux related symptoms.
Relapse in the subgroup of patients who relapsed in both maintenance
periods was infrequent on omeprazole 20 mg daily: only 9% at two
years. Gastrin concentrations rose above normal in one third of
patients. One patient had linear hyperplasia of endocrine cells and
another had micronodular hyperplasia. There were no side effects
definitely attributable to omeprazole.
Conclusion
Maintenance treatment with omeprazole
10 mg daily keeps about 60% of patients with erosive oesophagitis in
prolonged remission. Patients relapsing once are likely to do so again; they can subsequently be treated effectively with omeprazole 20 mg daily.
(GUT 1998;43:458-464)
© 1998 by Gut
This article has been cited by other articles:
-
Sharma, N, Donnellan, C, Preston, C, Delaney, B, Duckett, G, Moayyedi, P
(2004). A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials. Gut
53: iv58-iv65
[Abstract] [Full Text] -
Wu, J C Y, Chan, F K L, Ching, J Y L, Leung, W-K, Hui, Y, Leong, R, Chung, S C S, Sung, J J Y
(2004). Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut
53: 174-179
[Abstract] [Full Text] -
Dent, J., Jones, R., Kahrilas, P., Talley, N. J
(2001). Management of gastro-oesophageal reflux disease in general practice. BMJ
322: 344-347
[Full Text] -
Bardhan, K D, Müller-Lissner, S, Bigard, M A, Porro, G B., Ponce, J, Hosie, J, Scott, M., Weir, D G, Gillon, K R W, Peacock, R A, Fulton, C.
(1999). Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. BMJ
318: 502-507
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
